Page 119 - Read Online

Simsek et al. Hepatoma Res 2020;6:11 I http://dx.doi.org/10.20517/2394-5079.2019.51 Page 5 of 10

Table 2. Alpha fetoprotein levels pre and post-liver transplant
Patient Pre-LT AFP Initial post-LT AFP AFP at recurrence
1 9 7 2019
2 28,139 365,210 NA
3 135 4.1 15
4 3.6 0.6 1.7
5 27 3864 NA
6 488 57 86
7 22 2 26
8 23 12 1416
9 162 6.4 7
10 169 682 3342
11 34 3 389
12 48 4 12
13 323 76 157
14 7 21 NA
15 23 10 51
16 4659 25,154 NA
17 304 35 5.4
18 3.3 4.3 210
19 1707 100 47,304
20 34 2 3.7
21 680,000 217,576 120,848
22 22 2 17
23 4 2 NA
24 207 317 40.9
25 486 104 3677
26 5.2 5.5 4
Alpha fetoprotein levels (ng/mL) pre- and post-liver transplant in 26 liver transplant recipients with hepatocellular carcinoma recurrence.
AFP: alpha fetoprotein; LT: liver transplant; NA: data not available

Figure 2. Overall, per year rate of hepatocellular carcinoma recurrence in deceased donor liver transplant recipients at the Johns Hopkins
Hospital from 2005 to 2015. HCC: hepatocellular carcinoma